GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (FRA:C1P) » Definitions » Retained Earnings

Consun Pharmaceutical Group (FRA:C1P) Retained Earnings : €446.8 Mil (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Consun Pharmaceutical Group's retained earnings for the quarter that ended in Dec. 2024 was €446.8 Mil.

Consun Pharmaceutical Group's quarterly retained earnings declined from Dec. 2023 (€403.4 Mil) to Jun. 2024 (€395.7 Mil) but then increased from Jun. 2024 (€395.7 Mil) to Dec. 2024 (€446.8 Mil).

Consun Pharmaceutical Group's annual retained earnings increased from Dec. 2022 (€362.5 Mil) to Dec. 2023 (€403.4 Mil) and increased from Dec. 2023 (€403.4 Mil) to Dec. 2024 (€446.8 Mil).


Consun Pharmaceutical Group Retained Earnings Historical Data

The historical data trend for Consun Pharmaceutical Group's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group Retained Earnings Chart

Consun Pharmaceutical Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 300.12 362.50 403.36 446.78

Consun Pharmaceutical Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 362.50 363.07 403.36 395.73 446.78

Consun Pharmaceutical Group Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Consun Pharmaceutical Group  (FRA:C1P) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Consun Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.

Consun Pharmaceutical Group Headlines

No Headlines